US Drug Recall Register
Class II · Moderate risk Terminated Initiated Aug 3, 2016 (10 years ago)

Pantoprazole Sodium Delayed-Release Tablets USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Tablets/Capsules: Firm received a market complaint stating the presence of one foreign tablet (Montelukast Sodium Chewable Tab 4mg) in the product bottle of Pantoprazole.

What was recalled

Pantoprazole Sodium Delayed-Release Tablets USP, 40 mg Rx Only, 90 tablets per bottle, Manufactured for Aurobindo Pharma USA, Inc 2400 Route 130 North Dayton, NJ 08810, Manufactured by: Aurobindo Pharma Limited Unit-VII (SE2), Mahaboob Nagar (Dt) - 509302, India , NDC 65862-0560-90

Recalling firm
Aurobindo Pharma USA Inc
NDC code
65862-0560-90
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1499-2016

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Pantoprazole recalls

See all
Class II · Moderate risk Ongoing

Pantoprazole Sodium

Reason Discoloration: Firm received five (5) complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots."

Hetero Labs Limited (Unit V) NDC 31722-713-10 D-0484-2026
Class II · Moderate risk Terminated

Pantoprazole Sodium for Injection 40mg per vial

Reason Lack of Assurance of Sterility: Powder discoloration due to small crack in some vials.

Be Pharmaceuticals Ag NDC 71839-122-01 D-1148-2023
Class II · Moderate risk Completed

Pantoprazole sodium for Injection 40 mg*/vial

Reason CGMP Deviations; The impacted product and lot number was inadvertently placed into saleable inventory, which does not comply with approved procedures.

Methapharm Inc NDC 67850-150-10 D-0540-2023
Class II · Moderate risk Terminated

Pantoprazole 30mg in Ns 7.5ml

Reason Lack of sterility assurance

Sentara Infusion Services D-0313-2023